---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-22-000003"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:17:33.412054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Bio pre-announces Q4 rev $4.7-5.2M; FY22 outlook $27-32M

## Summary
- Preliminary Q4 total revenue $4.7M-$5.2M; commercial $4.5M-$4.9M; non-commercial (BARDA) $0.2M-$0.3M.
- Full year 2021 total revenue $22.8M-$23.3M; commercial $21.3M-$21.7M; placed 29 systems, validated 33.
- Recurring revenue grew ~90% in Q4 vs prior-year period; 16 systems validated in Q4.
- FY2022 commercial revenue outlook $27M-$32M, 25%-50% growth over preliminary FY2021 commercial revenue.
- Ended 2021 with >$200M cash and investments, zero debt; COVID headwinds impacted Q4 placements.

## SEC filing metadata
- accession: 0001380106-22-000003
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000003/0001380106-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000003/c106-20220109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-22-000003
- JSON: https://secwatch.observer/filing/0001380106-22-000003.json
- Plain text: https://secwatch.observer/filing/0001380106-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.